2015 Articles
A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy
Glioblastoma multiforme (GBM) is the most common primary brain tumor and among the most difficult to treat malignancies per se. In almost 90% of all GBM alterations in the PI3K/Akt/mTOR have been found, making this survival cascade a promising therapeutic target, particular for combination therapy that combines an apoptosis sensitizer, such as a pharmacological inhibitor of PI3K, with an apoptosis inducer, such as radio- or chemotherapy. However, while in vitro data focusing mainly on established cell lines has appeared rather promising, this has not translated well to a clinical setting. In this study, we analyze the effects of the dual kinase inhibitor PI-103, which blocks PI3K and mTOR activity, on three matched pairs of GBM stem cells/differentiated cells. While blocking PI3K-mediated signaling has a profound effect on cellular proliferation, in contrast to data presented on two GBM cell lines (A172 and U87) PI-103 actually counteracts the effect of chemotherapy. While we found no indications for a potential role of the PI3K signaling cascade in differentiation, we saw a clear and strong contribution to cellular motility and, by extension, invasion. While blocking PI3K-mediated signaling concurrently with application of chemotherapy does not appear to be a valid treatment option, pharmacological inhibitors, such as PI-103, nevertheless have an important place in future therapeutic approaches.
Files
-
journal.pone.0131670.pdf application/pdf 953 KB Download File
-
journal.pone.0134770.PDF application/pdf 44.7 KB Download File
Also Published In
- Title
- PLOS ONE
- DOI
- https://doi.org/10.1371/journal.pone.0131670
More About This Work
- Academic Units
- Pathology and Cell Biology
- Published Here
- December 20, 2017
Notes
Included: 30 Jul 2015: The PLOS ONE Staff (2015) Correction: A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma Therapy. PLOS ONE 10(7): e0134770. https://doi.org/10.1371/journal.pone.0134770